Qiagen N.V. (QGEN)
Stock Price Chart
Key Info
| Market Cap | 11.09B |
| Revenue (ttm) | 1.71B |
| Net Income (ttm) | 163.12M |
| Shares Out | 228.75M |
| EPS (ttm) | 0.83 |
| PE Ratio | 58.42 |
| Forward PE | 19.31 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 27 |
| Last Price | $48.49 |
| Previous Close | $47.25 |
| Change ($) | 1.24 |
| Change (%) | 2.62% |
| Day's Open | 48.50 |
| Day's Range | 48.09 - 48.63 |
| Day's Volume | 535,143 |
| 52-Week Range | 30.23 - 55.27 |
More Stats
| Market Cap | 11.09B |
| Enterprise Value | 12.37B |
| Earnings Date (est) | Feb 3, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 228.75M |
| Float | 224.92M |
| EPS (basic) | 0.70 |
| EPS (diluted) | 0.83 |
| FCF / Share | 0.76 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 1.71% |
| FCF Yield | 1.62% |
| Payout Ratio | n/a |
| Shares Short | 4.55M |
| Short Ratio | 4.45 |
| Short % of Float | 2.02% |
| Beta | 0.41 |
| PE Ratio | 58.42 |
| Forward PE | 19.31 |
| P/FCF Ratio | 61.89 |
| PS Ratio | 6.48 |
| PB Ratio | 3.93 |
| Revenue | 1.71B |
| Operating Income | 287.11M |
| Net Income | 163.12M |
| Free Cash Flow | 179.23M |
| Net Cash | -1.28B |
| Net Cash / Share | -5.61 |
| Gross Margin | 62.87% |
| Operating Margin | 16.76% |
| Profit Margin | 9.50% |
| FCF Margin | 10.47% |
| ROA | 5.05% |
| ROE | 7.39% |
| ROIC | 10.80% |
Analyst Forecasts
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,526 | 1,502 | 1,418 | 1,338 | 1,281 | 1,345 | 1,302 | 1,254 | 1,170 | 1,087 |
| Revenue Growth | 1.64% | 5.95% | 5.95% | 4.45% | -4.74% | 3.29% | 3.79% | 7.24% | 7.57% | - |
| Gross Profit | 998 | 993 | 923 | 845 | 827 | 865 | 815 | 824 | 750 | 716 |
| Operating Income | -49.53 | 273 | 153 | 98.83 | 179 | 162 | 63.33 | 170 | 99.59 | 189 |
| Net Income | -69.77 | 105 | 40.39 | 80.40 | 130 | 116 | 69.07 | 130 | 96.04 | 144 |
| Shares Outstanding | 227 | 227 | 228 | 235 | 233 | 233 | 225 | 227 | 225 | 224 |
| Earnings Per Share | -0.31 | 0.45 | 0.17 | 0.34 | 0.56 | 0.50 | 0.31 | 0.57 | 0.43 | 0.64 |
| EPS Growth | - | 164.71% | -50% | -39.29% | 12% | 60.26% | -45.36% | 34.04% | -33.85% | - |
| Operating Cash Flow | 331 | 359 | 287 | 342 | 317 | 288 | 259 | 245 | 245 | 251 |
| Capital Expenditures | -118 | -110 | -90.04 | -74.47 | -97.68 | -86.56 | -84.42 | -101 | -84.79 | -76.19 |
| Free Cash Flow | 213 | 250 | 197 | 267 | 220 | 201 | 175 | 144 | 160 | 175 |
| Cash & Equivalents | 759 | 1,374 | 1,017 | 532 | 427 | 578 | 381 | 485 | 276 | 934 |
| Total Debt | 1,706 | 2,175 | 1,758 | 1,067 | 1,044 | 1,157 | 845 | 843 | 577 | 873 |
| Net Cash / Debt | -947 | -802 | -741 | -535 | -617 | -579 | -465 | -357 | -300 | 61.48 |
| Assets | 5,236 | 5,798 | 5,039 | 4,308 | 4,193 | 4,445 | 4,092 | 4,122 | 3,834 | 3,914 |
| Liabilities | 2,699 | 3,419 | 2,498 | 1,701 | 1,696 | 1,853 | 1,305 | 1,327 | 1,201 | 1,438 |
| Book Value | 2,537 | 2,379 | 2,541 | 2,607 | 2,495 | 2,584 | 2,777 | 2,784 | 2,623 | 2,476 |
Company Profile
Company Details
| Full Name | Qiagen N.V. |
| Country | Netherlands |
| Employees | 5,300 |
| CEO | Thierry Bernard |
Stock Information
| Ticker Symbol | QGEN |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NYSE: QGEN |
| IPO Date | June 28, 1996 |
Description
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels (DNA and RNA), library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc., CLIA-certified laboratories, and NuProbe Global. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.